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Objective: A decade after the first report of descending thoracic aortic aneurysm (DTA) repair with endografts, a
commercial device is yet to be approved in the United States. The GORE TAG endoprosthesis, an investigational
nitinol-supported expanded polytetrafluoroethylene tube graft with diameters of 26 to 40 mm, is the first DTA device to
enter phase II trials in the United States and has been used worldwide for a host of thoracic pathologies.
Methods: A multicenter prospective nonrandomized phase II study of the GORE TAG endoprosthesis was conducted at
17 sites. Enrollment was from September 1999 to May 2001. Preoperative workup included arteriography and spiral
computed tomography scans of the chest, abdomen, and pelvis. Follow-up radiographs and computed tomography scans
were obtained at 1, 6, and 12 months and yearly thereafter.
Results: A total of 139 (98%) of 142 patients had a successful implantation of the device. Inadequate arterial access was
responsible for the 3 failures. The mean DTA size was 64.1 15.4 mm.Men slightly outnumbered women (57.7%), with
an average age of 71 years, and 88% of the patients were white. Ninety percent were American Society of Anesthesiologists
category III or IV. One device was used in 44% of patients, and 56% required two or more devices to bridge the thoracic
aorta. The left subclavian artery was covered in 28 patients, with planned carotid-subclavian transposition. The procedure
time averaged 150 minutes, estimated blood loss averaged 506 mL, intensive care unit stay averaged 2.6 days, and
hospital stay averaged 7.6 days. Within 30 days, 45 (32%) patients had at least 1 major adverse event: 5 (4%) experienced
a stroke, 4 (3%) demonstrated temporary or permanent paraplegia, 20 (14%) experienced vascular trauma or thrombosis,
and 2 (1.5%) died. Mean follow-up was 24.0 months. Four patients had aneurysm-related deaths. Three patients
underwent endovascular revisions for endoleak. No ruptures have been reported. Twenty wire fractures have been
identified in 19 patients; 18 (90%) of these occurred in the longitudinal spine, and only 1 patient required treatment. At
2 years, aneurysm-related and overall survival rates are 97% and 75%, respectively.
Conclusions: The GORE TAG thoracic endoprosthesis provides a safe alternative for the treatment of DTAs, with low
mortality, relatively low morbidity, and excellent 2-year freedom from aneurysm-related death. Longitudinal spine
fractures have so far been associated with rare clinical events. ( J Vasc Surg 2005;41:1-9.)Descending thoracic aortic aneurysms (DTAs) are less
prevalent than their abdominal counterparts and are esti-
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doi:10.1016/j.jvs.2004.10.046mated to affect 10 of every 100,000 elderly adults.1 Thirty
to forty percent of these aneurysms occur exclusively in the
descending thoracic aorta.1,2 Open repair of DTAs has
traditionally been a procedure associated with high mor-
bidity and mortality and has been offered only to good
surgical candidates. Perioperative death rates exceeding
10%, a risk of paraplegia of 4% to 5%, and a long recovery
from thoracotomy make this a weighty undertaking for
surgeon and patient alike.3,4
Endovascular repair of thoracic aneurysms offers the ben-
efit of aneurysm exclusion without the physiologic insult of
prolonged proximal aortic clamping and direct surgical expo-
sure, which may improve early morbidity.5,6 Higher-risk pa-
tients previously denied open treatment might also benefit
from this less invasive approach.
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was evaluated early in both the abdominal and thoracic
aorta,7,8 commercial development of thoracic endografts
has lagged behind the rush to introduce stent grafts suitable
for the more common abdominal aortic aneurysms. No
thoracic devices have yet gained regulatory approval in the
United States, whereas four abdominal products have been
marketed since 1999. The GORE TAG thoracic endopros-
thesis (TAG; W.L. Gore, Flagstaff, Ariz) was the first tho-
racic device to enter clinical trials in the United States, in
1998. The trial was halted in November 2001 after the
discovery of longitudinal spine fractures. A new trial was
initiated in late 2003 with a slightly modified device. This
study reports the clinical results of the initial phase II
multicenter trial of the original TAG device in the treat-
ment of descending DTA.
METHODS
Enrollment. Enrollment in this prospective, nonran-
domized study occurred from September 1999 to May
2001 at 17 institutions across the United States (Appen-
dix). Surgical candidates with a DTA twice as large as the
normal thoracic aorta adjacent to the aneurysm underwent
detailed preoperative spiral computed tomography (CT)
scanning and diagnostic arteriography. Proximal and distal
landing zones of a suitable diameter and at least 2 cm long
Table I. Anatomic and medical inclusion and exclusion
criteria for the GORE TAG trial
Inclusion criteria
Anatomic
Descending TAA at least twice the size of the normal
thoracic aorta (fusiform aneurysm)
Minimum 2 cm of normal thoracic aorta proximal and distal
to aneurysm
Aortic taper of no more than 4 mm, or ability to treat with
more than one graft
Medical
Life expectancy 2 y
Surgical candidate
Male or infertile female 21 y
Able to comply with consent and follow-up
Exclusion criteria
Anatomic
Significant thrombus in landing zones
Mycotic aneurysm
Unstable patient with rupture
Acute or chronic dissection
Planned occlusion of carotid or celiac arteries to seal
Medical
Major operation (other than planned subclavian to carotid
transposition or bypass) within 30 d
MI or CVA within 6 wk
Creatinine 2.0 mg/dL not on dialysis
Connective tissue disorder
Documented drug abuse within 6 mo
Participation in another investigational device or drug study
within 1 y
TAA, Thoracoabdominal aorta; MI, myocardial infarction; CVA, cerebro-
vascular accident.were required. The proximal landing zone had to be distalto the left common carotid artery. If the left subclavian
artery was covered to achieve this zone, then a carotid to
subclavian artery bypass was performed. A 7% to 18%
oversizing of endoprosthesis to artery was recommended
by the device manufacturer. Select anatomic and medical
inclusion and exclusion criteria are listed in Table I. A
nonrandomized group of open-repair DTA patients from
the same institutions were enrolled in the study and fol-
lowed up. The surgical results of this group are not re-
ported here because of regulatory requirements pending
review by the Food and Drug Administration.
Follow-up protocol. CT scans, plain radiographs,
and physical examinations were obtained at 1, 6, and 12
months and yearly thereafter. A 3-month visit with a CT
scan was also included in patients with an early endoleak
seen at 1 month. Clinical data were reported by individual
centers and monitored by sponsor representatives. Major
adverse events were adjudicated by a Clinical Events Com-
mittee, and source documents were reviewed by the au-
thors for this report. A core laboratory separately reviewed
all imaging studies. Major adverse events were defined as
clinical events that required therapy or those that resulted
in an unplanned increase in the level of care, prolonged
hospitalization, permanent adverse sequelae, or death.9
Migration was defined as displacement of all or part of the
device sufficient to be associated with another complication
(eg, endoleak) or more than 1 cm of movement of all or
part of the device as seen by CT or chest radiograph.
Aneurysm sac size change was defined by a diameter in-
crease or decrease of 5 mm or more. All imaging-related
data are reported as collected by the core laboratory unless
otherwise indicated. Clinical data reported here are from
the compilation of monitored research forms from the sites
except for changes made by the Clinical Events Committee
in conjunction with the authors after careful review of
source documents involved. Results are reported as mean
SD (range) where appropriate. Kaplan-Meier curves and
log-rank tests were used to plot survival over time, and the
2 test was used to compare nominal data. P  .05 was
considered significant.
Device description and deployment. The TAG en-
doprosthesis is a flexible nitinol-supported polytetrafluoro-
ethylene (PTFE) graft available in diameters of 26 to 40
mm and in 10-, 15-, and 20-cm lengths. During the trial,
7.5- and 12.5-cm lengths were also available but have since
been discontinued. The exoskeleton is bonded to the graft
material without sutures and is constrained by a PTFE
sleeve. The device profile depends on the size of the graft
and requires a 20F to 24F sheath. Deployment is very rapid
and occurs with the release of the constraining sleeve. The
TAG expansion is designed to start from the middle of the
endoprosthesis and progress toward the ends of the graft
(Fig 1). This is designed to avoid the displacing forces of
the high arterial flow when the device is partially deployed
in a standard deployment mode. The device is then addi-
tionally expanded with a specially designed trilobed balloon
that allows flow to continue during inflation (Fig 2). If
more than one device was used, the most proximal device
nce o
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to this with at least 2 cm of overlap. The original device
used in the phase II trial reported here contained two
longitudinal spines for columnar support. The device has
been redesigned recently: the longitudinal spine was re-
moved, and the expanded PTFE material was reinforced
(Fig 3). All procedures were performed under fluoroscopy
by using standard endovascular techniques.
The protocol and procedures of this trial were approved
by the Food andDrug Administration and by the individual
institutional review boards of each participating center.
Patients signed a research informed consent form before
participation in the study.
RESULTS
Demographics. One hundred forty-two patients sat-
isfied all inclusion and exclusion criteria and were enrolled
Fig 1. Deployment sequeand scheduled to receive the TAG thoracic endoprosthesis.The average aneurysm size was 64.1  15.4 mm (range,
20-110 mm). Men slightly outnumbered women (58% vs
42%), with an average age of 71 years (range, 30-86 years),
and 88% of the patients were white. Medical comorbidities
are listed in Table II. One hundred seven patients (90%)
were American Society of Anesthesiologists category III or
IV.
Procedure and hospital course. One hundred thirty-
nine of 142 patients had successful deployment of their
TAG device(s). The three failures of deployment were all
secondary to access issues related to iliac vessel size and
tortuosity. Twenty-one patients (15%) had a conduit placed
to advance the device to the thoracic aorta. The location of
the conduit varied from the external iliac artery to the
infrarenal aorta to bypass inadequate access vessels from the
femoral region. Two hundred thirty-seven devices were
used to bridge the thoracic aneurysm: 62 (44%) patients
f the GORE TAG device.received 1 device, 61 (43%) patients received 2 devices, 11
signe
ws il
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quired 4 devices. Procedure time averaged 150  74 min-
utes (range, 61-580 minutes), with 506 945 mL (range,
0-8000 mL) of blood loss. Time in the intensive care unit
averaged 2.6  14.6 days (range, 0-167 days), with a
median of 1 day. The total hospital stay was 7.6  18 days
(range, 1-190 days), with a median of 3 days. The left
Fig 3. Original (left) and re-de
Fig 2. Trilobed balloon with arrosubclavian artery was covered in 28 cases after a planned leftcarotid-subclavian bypass to preserve subclavian flow when
the artery was covered by the thoracic stent graft. Sixteen
carotid-subclavian bypasses were performed as staged pro-
cedures, and 12 patients had this operation completed on
the same day as the thoracic stent placement. Two inadver-
tent side branch coverages were noted: one of the subcla-
vian artery (requiring no treatment) and another of the
d (right) GORE TAG devices.
lustrating flow-through channels.abdominal visceral vessels. The latter patient underwent an
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redeployment of new devices across the thoracic aneurysm
without trauma to the visceral vessels.
Adverse events. Early and late adverse events are
detailed in Table III. Major adverse events within 30
days were noted in 45 (32%) patients, and several had
more than 1. The most common were bleeding, cardio-
pulmonary events, and vascular trauma during the pro-
cedure. All vascular trauma events were in the perioper-
ative period.
Aneurysm-related mortality. There were three in-
hospital deaths, for an operative mortality of 2%. One early
death was due to a postoperative stroke and another to a
cardiac event that occurred on postoperative day 11. The
third death occurred nearly 7 months after the procedure
from a long complicated course following an anoxic brain
injury after respiratory arrest. This patient eventually died
of septic complications and was found at autopsy to have
Table III. Early and late major adverse events
Complications 30 d No. of Patients (%)
Any major 45 (32)
Bleeding complications—all 12 (9)
Any endoleak 5 (4)
Pulmonary 14 (10)
Cardiac 4 (3)
Vascular trauma/thrombosis 20 (14)
Stroke 5 (4)
Paraplegia/paraparesis 4 (3)
Death 2 (1.5)
Late events 1-y patients (%) 2-y patients (%)
Migration—proximal* 0/97 (0) 3/68 (4)
Migration—components* 1/84 (1) 4/61 (6)
Endoleak rate* 7/97 (7) 6/68 (9)
Size decrease 5 mm* 23/83 (28) 24/64 (38)
Size increase 5 mm* 6/83 (7) 11/64 (17)
Endovascular revision 1 1
Conversion to open 1 (1) 0
Ruptures 0 0
Aneurysm-related death 2 (1.5) 0
*Core laboratory reports.
Table II. Medical comorbidities of GORE TAG patients
Parameter No. of Patients (%)
Coronary artery disease 70 (49)
Cardiac arrhythmia 34 (24)
Congestive heart failure 13 (9)
Stroke 14 (10)
Symptomatic aneurysm 32 (23)
Aneurysm of traumatic origin 8 (6)
COPD 56 (39)
Smoking history 118 (83)
Dialysis 3 (2)
Paraplegia 1 (1)
COPD, Chronic obstructive pulmonary disease.had an aortoesophageal fistula. The only other aneurysm-related death occurred 2 months after the original proce-
dure after surgical conversion for aneurysm enlargement
and suspected infection. At conversion, the patient was
found to have an aortoesophageal fistula that was success-
fully excluded with graft removal and extra-anatomic by-
pass. On postoperative day 13, the patient experienced
respiratory arrest and sustained an anoxic brain injury. He
died 3 days later.
Cerebrovascular accidents. Five patients (3.5%) had
a perioperative stroke. One stroke was fatal, and four pa-
tients were discharged to a rehabilitation facility or home.
Three of five strokes affected both the anterior and poste-
rior circulation distributions, and three were right-sided.
Of the two left-sided strokes, one patient had a carotid-
subclavian bypass. The strokes clustered in patients with
proximal aneurysmal disease who were undergoing a
carotid-subclavian bypass in preparation for the endograft
placement. Four (80%) of the five patients with a stroke had
a planned bypass either as a staged intervention (n  2) or
in conjunction with the endovascular procedure (n 2). In
total, 4 of 28 patients undergoing the carotid-subclavian
intervention (14%) had a cerebrovascular event after the
TAG procedure, compared with 1% of patients who did not
have a carotid-subclavian bypass (P  .001).
Spinal ischemia. Spinal drainage was not routinely
used during the interventions. Four patients had spinal
cord events in their postoperative course, and three had
spinal drains placed at the time the deficits were noted.
Immediately after the procedure, one patient was noted to
have bilateral lower extremity weakness. Despite spinal
drainage, the deficits persisted, and she was discharged in
this condition. A second patient exhibited paraplegia 6
hours after surgery in conjunction with a hypotensive epi-
sode. These symptoms improved after the patient was
stabilized and a drain was placed. At last follow-up, this
patient was ambulating with a walker. A third patient
exhibited lower extremity weakness and numbness on post-
operative day 1. She improved by the time of discharge and
was near baseline at 1 month after her procedure. A fourth
patient was noted on postoperative day 1 to have decreased
strength in the proximal muscles of the legs. This was
treated with aggressive blood pressure support and had
improved 24 hours later. She was discharged to a rehabili-
tation facility with good strength in all extremities. It is of
note that three of four patients had more than one device
implanted (two, three, and four devices). Two of the four
patients also had an abdominal aneurysm previously treated
with aortobifemoral bypass. Forty-two (29.6%) TAG pa-
tients had previous infrarenal aortic replacement, resulting
in a 4.7% rate of spinal cord events in this subgroup.
Paraplegia in patients without abdominal aortic replace-
ment was 2% (P  .36; not significant).
Endoleaks. Of five early endoleaks at 30 days, one
patient had a proximal type I endoleak and was treated with
endovascular revision and additional grafts. This patient
had an additional endovascular revision after 24 months of
follow-up. The remaining endoleaks were thought to be
type II. At 1 and 2 years, the rates of observed endoleaks
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treated by endovascular revision: one during the second
year and one during the third year of follow-up. Because
endoleaks were not consistently observed in the same pa-
tient at all times, 21 patients (15%) had an endoleak at some
time during the first 2 years of follow-up. Most endoleaks
were of undetermined origin on CT scan. Three patients
who had endoleaks at some time were also found to have
sac expansion of 5 mm or more.
Follow-up. Average follow-up for this report was 728
days (24.0 months), with a range of 3 to 1626 days. Fig 4
depicts a Kaplan-Meier survival curve showing freedom
from all mortality and aneurysm-related mortality. At 2
years, the rates are 75% and 97%, respectively. No ruptures
were reported.
Late events are also noted in Table III. Four endovas-
cular revisions in three patients and one surgical conversion
were reported during follow-up; two of the revisions oc-
curred after 24 months of follow-up. At 2 years, three
proximal and four component migrations were noted by
the core laboratory, without associated clinical events. An-
eurysm sacs decreased in size in 24 (38%) of 64 patients,
and size increased in 11 (17%). Three of the 11 patients
with sac expansion had endoleaks at some point during
follow-up. Twenty fractures have so far been identified in
19 patients at 2 years. Eighteen (90%) of 20 fractures were
Fig 4. Kaplan-Meier curves of aneurysmin the longitudinal spine, and only 2 were in the apicalnitinol support rings. One patient had a fracture in the
spine and the ring. Only one patient with a fracture has so
far developed a clinical event. This was a type 3 endoleak
corrected by an endovascular deployment of a new device.
DISCUSSION
The natural history of DTAs and the morbidity and
mortality of open repair are not well known, because most
series combine them with more extensive thoracoabdomi-
nal aneurysms. Perioperative mortality as high as 10% and
paraplegia rates approaching 4% to 5% have been reported
in selected series.3,4 These risks can be prohibitive in an
elderly population. However, with a greater than 30%
5-year risk of rupture or death when the aneurysm is larger
than 6 cm, there is a clear need for prophylactic repair of
large aneurysms.10 Endovascular treatment of DTAs may
offer both short- and long-term advantages when com-
pared with open surgery, because it avoids a thoracotomy
and thoracic aortic clamping.
The feasibility of endovascular treatment of DTAs was
first reported in a high-risk population by Dake et al7 in
1994, who used homemade devices consisting of Dacron-
covered (DuPont, Wilmington, Del) Gianturco Z-stents.
As experience accumulated, significant limitations of a stiff
device with a large introducer size became evident.11 Long-
term results in high-risk patients, especially those deemed
ted and non–aneurysm-related survival.-relainoperable or those requiring arch deployment after a ca-
JOURNAL OF VASCULAR SURGERY
Volume 41, Number 1 Makaroun et al 7rotid subclavian bypass, were far less than acceptable, which
led the group to nearly abandon this first-generation de-
vice.5 Other groups using similar constructions also en-
countered serious complications, including a mortality rate
as high as 25%, late ruptures, and migrations.12
The advent of commercially manufactured grafts based
on technology developed for the treatment of abdominal
aneurysms brought the promise of a smaller, more flexible,
andmore durable prostheses. Experience with these devices
is accumulating worldwide in a variety of clinical settings.
Indications have been expanded to include dissections,
traumatic injuries, and other thoracic pathology. Early sin-
gle-center results are promising, with improved mortality
and morbidity.6,13 Criado et al,6 using the Talent device
(Medtronic AVE, Santa Rosa, Calif), and White et al,14
using the AneuRx device (Medtronic AVE), both reported
a 4% aneurysm-related mortality in series of both DTAs and
dissections. Only 1 patient of the 74 treated by these 2
groups developed paralysis.
The TAG device was the first commercial device to
enter trials in the United States. Single-center experiences
in high-risk applications have confirmed a low mortality of
4% to 6% and a very low paraplegia rate.15,16 The phase II
results of the TAG device presented here illustrate a safe
and technically successful means of treating a larger popu-
lation of selected patients with DTAs. These elderly pa-
tients with significant cormorbidities, who were over-
whelmingly American Society of Anesthesiologists class III
or IV, had very lowmortality and spinal ischemia rates of 2%
each while having a high rate of successful deployment and
aneurysm exclusion. These encouraging early and mid-
term results cannot at present be compared with the “sur-
gical control group” because of regulatory requirements,
but they seem to improve on historical standards.
The TAG device has many technical advantages, in-
cluding a very rapid deployment from the center of the graft
out, which has eliminated the need for temporary cardiac
arrest with adenosine.17 In addition, the flexibility of the
TAG catheter is well suited to navigate tortuous anatomy
and to be deployed in the aortic arch. The proximal end of
the device was deployed in this series at the level of the left
carotid artery in 20% of patients. This manipulation in the
arch, however, was probably responsible for a significant
incidence (nearly 14%) of strokes in this subgroup of pa-
tients. The etiology was most likely embolic, because the
cerebral events were frequently multicentric and involved
the posterior circulation in at least three of five patients.
The associated carotid subclavian bypasses performed as
part of this protocol were probably only a marker for the
site of deployment and the associated risk, rather than the
cause of the strokes. Whether such an adjunctive procedure
is necessary in all cases is open to debate, because many
European centers have experienced few complications from
simply covering the left subclavian artery during such pro-
cedures.18
Although spinal cord events are always tragic, their 3%
rate noted with this phase II trial is quite low and is less than
many other reported ranges.12,15,19 Three of four patientswith lower extremity weakness had significant improve-
ment within short-term follow-up, and one had permanent
deficits. Two of the patients had previous abdominal aneu-
rysm surgery, and three had more than one graft placed to
cover a significant portion of the descending thoracic aorta.
These observations mirror other results showing that pa-
tients with previous aortic surgery and with long segments
of covered thoracic aorta have an increased incidence of
spinal cord events after thoracic endografting.19,20
Stent fractures, which led to the interruption of this
development program for more than 2 years, have proved
to be less of a clinical concern than initially anticipated.
Twenty fractures in 19 patients have been reported thus far
in patients enrolled in this phase II trial, and only 1 patient
has had a clinical event related to the fracture. Metal fatigue
andmaterial deterioration have been reported with virtually
every endograft used to date21 and are known complica-
tions of endoluminal treatment and product evolution.
Stent fractures seen with the TAG have been overwhelm-
ingly in the spine of the graft (18 of 20)—a feature that has
now been eliminated in the modified device in current
trials. Additional expanded PTFE thickness and reinforced
binding to the metal stent are expected to compensate for
the support previously provided by the longitudinal spine
and to thus avoid the possible side effects of fracture. This
revised design is currently under investigation. Because
most patients with spine fractures were asymptomatic, the
expectation is that the redesigned product will perform
similarly to the original product, at least in the early fol-
low-up phase. A finding that warrants close attention is the
number of patients who had sac enlargement after success-
ful DTA endograft placement. Seventeen percent of pa-
tients showed 5 mm or more of sac enlargement at the
24-month follow-up. The significance of this finding is
unknown. These are patients who have not all demon-
strated endoleak yet have expanding sac size. This phenom-
enon has been reported with the Excluder (W.L. Gore)
abdominal endoprosthesis22 and as yet has had no dire
clinical effects. The new modified TAG device has reduced
porosity, which may be of benefit for the cases of sac
enlargement.
Access to the thoracic aorta remains a significant issue
with endoluminal repair and accounts for all technical
failures in this report. Twenty patients had vascular compli-
cations even though 15% of patients required a conduit to a
larger part of the arterial tree. These rates are similar to
those in other reported series6,12,13 and underline the
importance of using conduits as a preventivemeasure rather
than a bailout after arterial injury has been noted. This
maneuver is quite important because sex distribution is far
more even with thoracic aneurysms compared with their
abdominal counterparts, as evidenced by 43% of the pa-
tients in this trial being women.
Future directions for thoracic stent grafting with the
TAG device may include use in rupture, acute type B
dissection, and a host of other thoracic pathologies. As
experience and comfort with the device increase, there may
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CONCLUSION
The TAG thoracic endoprosthesis provides a safe alter-
native for the treatment of DTAs, with low mortality,
relatively low morbidity, and an excellent 2-year freedom
from aneurysm-related death. Longitudinal spine fractures
have so far been associated with rare clinical events that will,
it is hoped, be eliminated by the modified version presently
undergoing clinical testing.
APPENDIX: TRIAL SITES AND PRINCIPAL
INVESTIGATORS
Institution City Investigator(s)
Baylor Houston, Tex Joseph Coselli, MD
Cleveland Clinic Cleveland, Ohio Roy Greenberg, MD
Emory Atlanta, Ga Elliot Chaikof, MD
Hartford Hospital Hartford, Conn Micheal Hallisey, MD
Johns Hopkins Baltimore, Md Lawrence Hoffman, MD
Massachusetts
General
Boston, Mass Richard Cambria, MD
Mayo Clinic Rochester, Minn Kenton Zehr, MD
Mt Sinai New York, NY Larry Hollier, MD
Northwestern Evanston, Ill Mark Marasch, MD
Stanford Stanford, Calif Steven Kee, MD
R. Scott Mitchell, MD
University of
Florida
Gainesville, Fla James Caridi, MD
James Seeger, MD
University of
Michigan
Ann Arbor, Mich David Williams, MD
University of
Pennsylvania
Philadelphia, Pa Joseph Bavaria, MD
Jeffrey Carpenter, MD
University of
Pittsburgh
Pittsburgh, Pa Michel Makaroun, MD
University of
South Carolina
Charleston, SC Renan Uflatker, MD
John Ikonomedis, MD
Washington
University
St Louis, Mo Gregorio Sicard, MD
Yale New Haven, Conn John Elefteriades, MD
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Dr R. Greenberg (Cleveland, Ohio). As the invited discus- in this trial and the other two commercial trials and that I have a
development agreement with Cook, Incorporated. Assuming that
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cessor studies have been designed, intentionally to avoid a rupture-
free survival end point, we’ve placed a heavy reliance on surrogate
end points, and wemust carefully consider these statistical analyses.
In the study design inherent with this article, the morbidity data
collected in a nonrandomized fashion and compared with histori-
cal controls must be called into question. There are no concurrent
controls, and there are potentially anatomic differences between
these groups. I would like you to address that. Assuming that we
agree that these comparisons are valid, we then need to turn our
attention to the surrogate end points. I would ask you what
surrogate end points you think are most predictive of long-term
rupture-free survival and the lack of need for secondary interven-
tions?
Our own conclusions have come to the assessment of both sac
size and migration data. In your article and presentation, these
circumstances were analyzed. However, the circumstances were
really analyzed by using, at least from what I can gather, two-
dimensional assessments of these criteria. In our experience, the
centerline of flow and three-dimensional offline reconstruction
have been imperative in the analysis of thoracic data.
The sac growth is also concerning and perhaps parallels the
sister abdominal device noted at 7% and 17% at 2 years. I question
whether this is different from the natural history of such aneurysms
without treatment and whether this is going to create long-term
complications.
Last, I would like you to comment on the two aortoesopha-
geal fistulas that developed in the first year after implantation, as
reported in the article, and perhaps you can elaborate on the
etiology of the strokes—whether they were thrombotic, embolic,
or otherwise created.
Dr Makaroun. The first question regards the comparison
with controls. As you can tell from my presentation, I strictly
avoided any comparison with controls, whether they were historic
or otherwise.
As far as the surrogate markers for the clinical success of the
therapy, including the size and the migration, the evaluation of
these by the core laboratory, as you do mention, is fraught with a
lot of sources of error. And, if you note, the numbers have changed
from the abstract, the numbers at 1 year until this presentation,
after additional detailed studies were re-evaluated. The size in-
crease that is noted at 1 and 2 years is slightly higher than you may
want to expect in a trial of this sort, but I have no way of telling
whether this is close to the natural history of these particular
patients. It is slightly lower than the abdominal component at this
time frame, but hopefully the change in the fabric that was insti-
tuted in the new device will have different results in the future.As far as the two aortoenteric fistulas that were described, the
first one is the one that led to the conversion and the death at 3
months, and the second one was actually discovered only at au-
topsy in the patient who was in the hospital for 6 months and died
from multiple septic problems.
Dr K. Cherry (Charlottesville, Va). I am intrigued about the
strokes. Presumably, the carotid subclavian bypasses were done to
prevent ischemia to the left subclavian, yet they seemed to be
incriminated a bit in the stroke rate. And it’s a follow-up question.
When were they done temporally in relation to the thoracic recon-
struction? And when was the stroke in relation to either the bypass
or the construction? Did you feel that the carotid subclavian bypass
played a role in the stroke?
Dr Makaroun. The five strokes that we identified were asso-
ciated with carotid subclavian bypasses, but we are not implicating
the bypass in the causation of the stroke but as an indicator of the
fact that it was required to deploy the device in the thoracic arch.
Unfortunately, despite having reviewed the source documents for
these, it is very hard to decide whether these were truly embolic or
thrombotic in nature.
The carotid subclavian bypasses were not all performed in
conjunction with the deployment of the device. Of the four
strokes, one was actually performed as a staged procedure before
the deployment of the device, and three of the four actually had the
carotid subclavian bypass or the transposition performed at the
same time. I was trying to point out only that the carotid subclavian
bypass is an indicator that when you are manipulating the arch with
both the wires and the deployment, you carry a significantly higher
chance of provoking a stroke than when the deployment is strictly
in the descending aorta past the subclavian.
Dr J. Parodi (St Louis, Mo). I have a short comment and a
question. The comment is that I believe that surgeons should be
prepared for rescue procedures and not accept the consequences of
stroke without attempting this. We have done this in eight pa-
tients. And the question is, in those cases of stroke, have you
attempted to study those patients and attempted any rescue pro-
cedure?
Dr Makaroun. I don’t think that in any of the five patients a
rescue procedure was performed. And I failed again to answer one
of the questions of Dr Cherry, about whether the timing of the
strokes was not after the staged carotid subclavian bypasses. Typi-
cally, they happened after the deployment of the device when the
patient woke up from anesthesia. Most of these patients were not
monitored to recognize the stroke intraoperatively. And a lot of
them were performed under general anesthesia. So it was not
recognized until the patient was waking up and the deficit was
recognized, and none had an attempted rescue.
